Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 662 entries
Sorted by: Best Match Show Resources per page
Past, present, and future of hormonal therapy in recurrent endometrial cancer.

International journal of women's health

Carlson MJ, Thiel KW, Leslie KK.
PMID: 24833920
Int J Womens Health. 2014 May 02;6:429-35. doi: 10.2147/IJWH.S40942. eCollection 2014.

Endometrial cancer is a heterogeneous disease. Type I cancers are hormonally driven, typically present with a low grade at an early stage, and are of endometrioid histology. These cancers are often cured by surgery, and the rate of recurrence...

Cite
Carlson MJ, Thiel KW, Leslie KK. Past, present, and future of hormonal therapy in recurrent endometrial cancer. Int J Womens Health. 2014;6:429-35doi: 10.2147/IJWH.S40942.
Carlson, M. J., Thiel, K. W., & Leslie, K. K. (2014). Past, present, and future of hormonal therapy in recurrent endometrial cancer. International journal of women's health, 6429-35. https://doi.org/10.2147/IJWH.S40942
Carlson, Matthew J, et al. "Past, present, and future of hormonal therapy in recurrent endometrial cancer." International journal of women's health vol. 6 (2014): 429-35. doi: https://doi.org/10.2147/IJWH.S40942
Carlson MJ, Thiel KW, Leslie KK. Past, present, and future of hormonal therapy in recurrent endometrial cancer. Int J Womens Health. 2014 May 02;6:429-35. doi: 10.2147/IJWH.S40942. eCollection 2014. PMID: 24833920; PMCID: PMC4014387.
Copy Download .nbib Format: NLM
Hormonal based treatment of ovarian anaplastic ependymoma with anastrozole.

Gynecologic oncology reports

Gorski JW, Taylor JS, Zhang J, Liu J, Jazaeri AA.
PMID: 28393092
Gynecol Oncol Rep. 2017 Mar 14;20:93-96. doi: 10.1016/j.gore.2017.03.005. eCollection 2017 May.

OBJECTIVE: Ovarian anaplastic ependymoma is a rare gynecologic malignancy that poses diagnostic and treatment challenges. Treatment of sub-optimally debulked disease usually portends poor prognosis. Molecular testing of tumor specimen can identify more specific targets for additional therapy such as...

Cite
Gorski JW, Taylor JS, Zhang J, et al. Hormonal based treatment of ovarian anaplastic ependymoma with anastrozole. Gynecol Oncol Rep. 2017;20:93-96doi: 10.1016/j.gore.2017.03.005.
Gorski, J. W., Taylor, J. S., Zhang, J., Liu, J., & Jazaeri, A. A. (2017). Hormonal based treatment of ovarian anaplastic ependymoma with anastrozole. Gynecologic oncology reports, 2093-96. https://doi.org/10.1016/j.gore.2017.03.005
Gorski, Justin Wayne, et al. "Hormonal based treatment of ovarian anaplastic ependymoma with anastrozole." Gynecologic oncology reports vol. 20 (2017): 93-96. doi: https://doi.org/10.1016/j.gore.2017.03.005
Gorski JW, Taylor JS, Zhang J, Liu J, Jazaeri AA. Hormonal based treatment of ovarian anaplastic ependymoma with anastrozole. Gynecol Oncol Rep. 2017 Mar 14;20:93-96. doi: 10.1016/j.gore.2017.03.005. eCollection 2017 May. PMID: 28393092; PMCID: PMC5376265.
Copy Download .nbib Format: NLM
Endometriosis: alternative methods of medical treatment.

International journal of women's health

Muñoz-Hernando L, Muñoz-Gonzalez JL, Marqueta-Marques L, Alvarez-Conejo C, Tejerizo-García Á, Lopez-Gonzalez G, Villegas-Muñoz E, Martin-Jimenez A, Jiménez-López JS.
PMID: 26089705
Int J Womens Health. 2015 Jun 11;7:595-603. doi: 10.2147/IJWH.S78829. eCollection 2015.

Endometriosis is an inflammatory estrogen-dependent disease defined by the presence of endometrial glands and stroma at extrauterine sites. The main purpose of endometriosis management is alleviating pain associated to the disease. This can be achieved surgically or medically, although...

Cite
Muñoz-Hernando L, Muñoz-Gonzalez JL, Marqueta-Marques L, et al. Endometriosis: alternative methods of medical treatment. Int J Womens Health. 2015;7:595-603doi: 10.2147/IJWH.S78829.
Muñoz-Hernando, L., Muñoz-Gonzalez, J. L., Marqueta-Marques, L., Alvarez-Conejo, C., Tejerizo-García, �. �., Lopez-Gonzalez, G., Villegas-Muñoz, E., Martin-Jimenez, A., & Jiménez-López, J. S. (2015). Endometriosis: alternative methods of medical treatment. International journal of women's health, 7595-603. https://doi.org/10.2147/IJWH.S78829
Muñoz-Hernando, Leticia, et al. "Endometriosis: alternative methods of medical treatment." International journal of women's health vol. 7 (2015): 595-603. doi: https://doi.org/10.2147/IJWH.S78829
Muñoz-Hernando L, Muñoz-Gonzalez JL, Marqueta-Marques L, Alvarez-Conejo C, Tejerizo-García Á, Lopez-Gonzalez G, Villegas-Muñoz E, Martin-Jimenez A, Jiménez-López JS. Endometriosis: alternative methods of medical treatment. Int J Womens Health. 2015 Jun 11;7:595-603. doi: 10.2147/IJWH.S78829. eCollection 2015. PMID: 26089705; PMCID: PMC4468987.
Copy Download .nbib Format: NLM
Influence of aromatase inhibitors therapy on the occurrence of rheumatoid arthritis in women with breast cancer: results from a large population-based study of the Italian Society for Rheumatology.

RMD open

Caprioli M, Carrara G, Sakellariou G, Silvagni E, Scirè CA.
PMID: 29071118
RMD Open. 2017 Sep 28;3(2):e000523. doi: 10.1136/rmdopen-2017-000523. eCollection 2017.

OBJECTIVES: The purpose of this study was to evaluate the risk of developing rheumatoid arthritis (RA) in a population of patients with breast cancer treated with aromatase inhibitors (AIs) compared with tamoxifen.METHODS: Data were collected from the administrative healthcare...

Cite
Caprioli M, Carrara G, Sakellariou G, et al. Influence of aromatase inhibitors therapy on the occurrence of rheumatoid arthritis in women with breast cancer: results from a large population-based study of the Italian Society for Rheumatology. RMD Open. 2017;3(2):e000523doi: 10.1136/rmdopen-2017-000523.
Caprioli, M., Carrara, G., Sakellariou, G., Silvagni, E., & Scirè, C. A. (2017). Influence of aromatase inhibitors therapy on the occurrence of rheumatoid arthritis in women with breast cancer: results from a large population-based study of the Italian Society for Rheumatology. RMD open, 3(2), e000523. https://doi.org/10.1136/rmdopen-2017-000523
Caprioli, Marta, et al. "Influence of aromatase inhibitors therapy on the occurrence of rheumatoid arthritis in women with breast cancer: results from a large population-based study of the Italian Society for Rheumatology." RMD open vol. 3,2 (2017): e000523. doi: https://doi.org/10.1136/rmdopen-2017-000523
Caprioli M, Carrara G, Sakellariou G, Silvagni E, Scirè CA. Influence of aromatase inhibitors therapy on the occurrence of rheumatoid arthritis in women with breast cancer: results from a large population-based study of the Italian Society for Rheumatology. RMD Open. 2017 Sep 28;3(2):e000523. doi: 10.1136/rmdopen-2017-000523. eCollection 2017. PMID: 29071118; PMCID: PMC5640089.
Copy Download .nbib Format: NLM
ER-positive breast cancer patients with more than three positive nodes or grade 3 tumors are at high risk of late recurrence after 5-year adjuvant endocrine therapy.

OncoTargets and therapy

Song F, Zhang J, Li S, Wu J, Jin T, Qin J, Wang Y, Wang M, Xu J.
PMID: 29042797
Onco Targets Ther. 2017 Oct 03;10:4859-4867. doi: 10.2147/OTT.S142698. eCollection 2017.

PURPOSE: Currently, although several clinical trials available give strong suggestions that extension of endocrine therapy has benefits, the risk level at which patients may benefit from extended endocrine therapy remains uncertain. This study aimed to identify the proportion of...

Cite
Song F, Zhang J, Li S, et al. ER-positive breast cancer patients with more than three positive nodes or grade 3 tumors are at high risk of late recurrence after 5-year adjuvant endocrine therapy. Onco Targets Ther. 2017;10:4859-4867doi: 10.2147/OTT.S142698.
Song, F., Zhang, J., Li, S., Wu, J., Jin, T., Qin, J., Wang, Y., Wang, M., & Xu, J. (2017). ER-positive breast cancer patients with more than three positive nodes or grade 3 tumors are at high risk of late recurrence after 5-year adjuvant endocrine therapy. OncoTargets and therapy, 104859-4867. https://doi.org/10.2147/OTT.S142698
Song, Fangbin, et al. "ER-positive breast cancer patients with more than three positive nodes or grade 3 tumors are at high risk of late recurrence after 5-year adjuvant endocrine therapy." OncoTargets and therapy vol. 10 (2017): 4859-4867. doi: https://doi.org/10.2147/OTT.S142698
Song F, Zhang J, Li S, Wu J, Jin T, Qin J, Wang Y, Wang M, Xu J. ER-positive breast cancer patients with more than three positive nodes or grade 3 tumors are at high risk of late recurrence after 5-year adjuvant endocrine therapy. Onco Targets Ther. 2017 Oct 03;10:4859-4867. doi: 10.2147/OTT.S142698. eCollection 2017. PMID: 29042797; PMCID: PMC5633314.
Copy Download .nbib Format: NLM
Targeted therapy for breast cancer prevention.

Frontiers in oncology

den Hollander P, Savage MI, Brown PH.
PMID: 24069582
Front Oncol. 2013 Sep 23;3:250. doi: 10.3389/fonc.2013.00250.

With a better understanding of the etiology of breast cancer, molecularly targeted drugs have been developed and are being testing for the treatment and prevention of breast cancer. Targeted drugs that inhibit the estrogen receptor (ER) or estrogen-activated pathways...

Cite
den Hollander P, Savage MI, Brown PH. Targeted therapy for breast cancer prevention. Front Oncol. 2013;3:250doi: 10.3389/fonc.2013.00250.
den Hollander, P., Savage, M. I., & Brown, P. H. (2013). Targeted therapy for breast cancer prevention. Frontiers in oncology, 3250. https://doi.org/10.3389/fonc.2013.00250
den Hollander, Petra, et al. "Targeted therapy for breast cancer prevention." Frontiers in oncology vol. 3 (2013): 250. doi: https://doi.org/10.3389/fonc.2013.00250
den Hollander P, Savage MI, Brown PH. Targeted therapy for breast cancer prevention. Front Oncol. 2013 Sep 23;3:250. doi: 10.3389/fonc.2013.00250. PMID: 24069582; PMCID: PMC3780469.
Copy Download .nbib Format: NLM
Aromatase inhibitors-induced bone loss in early breast cancer.

BoneKEy reports

Body JJ.
PMID: 24936287
Bonekey Rep. 2012 Oct 03;1:201. doi: 10.1038/bonekey.2012.201. eCollection 2012.

Women with breast cancer have an increased prevalence and incidence of fractures. This increased risk of fracture has become most evident following the use of aromatase inhibitors (AIs) as standard adjuvant therapy. AI-induced bone loss occurs at more than...

Cite
Body JJ. Aromatase inhibitors-induced bone loss in early breast cancer. Bonekey Rep. 2012;1:201doi: 10.1038/bonekey.2012.201.
Body, J. J. (2012). Aromatase inhibitors-induced bone loss in early breast cancer. BoneKEy reports, 1201. https://doi.org/10.1038/bonekey.2012.201
Body, Jean-Jacques. "Aromatase inhibitors-induced bone loss in early breast cancer." BoneKEy reports vol. 1 (2012): 201. doi: https://doi.org/10.1038/bonekey.2012.201
Body JJ. Aromatase inhibitors-induced bone loss in early breast cancer. Bonekey Rep. 2012 Oct 03;1:201. doi: 10.1038/bonekey.2012.201. eCollection 2012. PMID: 24936287; PMCID: PMC4056949.
Copy Download .nbib Format: NLM
Survival benefit of zoledronic Acid in postmenopausal breast cancer patients receiving aromatase inhibitors.

Journal of breast cancer

Ahn SG, Kim SH, Lee HM, Lee SA, Jeong J.
PMID: 25548583
J Breast Cancer. 2014 Dec;17(4):350-5. doi: 10.4048/jbc.2014.17.4.350. Epub 2014 Dec 26.

PURPOSE: A growing body of evidence indicates that zoledronic acid (ZA) can improve the clinical outcome in patients with breast cancer and low estrogen levels. In the present study, we aimed to investigate the survival benefit of ZA administration...

Cite
Ahn SG, Kim SH, Lee HM, et al. Survival benefit of zoledronic Acid in postmenopausal breast cancer patients receiving aromatase inhibitors. J Breast Cancer. 2014;17(4):350-5doi: 10.4048/jbc.2014.17.4.350.
Ahn, S. G., Kim, S. H., Lee, H. M., Lee, S. A., & Jeong, J. (2014). Survival benefit of zoledronic Acid in postmenopausal breast cancer patients receiving aromatase inhibitors. Journal of breast cancer, 17(4), 350-5. https://doi.org/10.4048/jbc.2014.17.4.350
Ahn, Sung Gwe, et al. "Survival benefit of zoledronic Acid in postmenopausal breast cancer patients receiving aromatase inhibitors." Journal of breast cancer vol. 17,4 (2014): 350-5. doi: https://doi.org/10.4048/jbc.2014.17.4.350
Ahn SG, Kim SH, Lee HM, Lee SA, Jeong J. Survival benefit of zoledronic Acid in postmenopausal breast cancer patients receiving aromatase inhibitors. J Breast Cancer. 2014 Dec;17(4):350-5. doi: 10.4048/jbc.2014.17.4.350. Epub 2014 Dec 26. PMID: 25548583; PMCID: PMC4278054.
Copy Download .nbib Format: NLM
Primary Hormone Therapy in Elderly Women with Hormone-Sensitive Locoregional Breast Cancer: Endocrine Therapy Alone Is a Reasonable Alternative in Selected Patients.

Breast care (Basel, Switzerland)

Quiroga-García V, Cirauqui-Cirauqui B, Bugés-Sánchez C, Luna-Tomás MÁ, Castellà-Fernández EM, Mariscal-Martínez A, Margelí-Vila M.
PMID: 26648829
Breast Care (Basel). 2015 Jul;10(3):179-83. doi: 10.1159/000382112. Epub 2015 May 22.

BACKGROUND: Treatment with aromatase inhibitors (AIs) followed by surgery is often recommended for women with locoregional hormone-sensitive breast cancer. However, no study has compared the efficacy of AIs alone versus AIs followed by surgery.METHODS: 33 postmenopausal breast cancer patients...

Cite
Quiroga-García V, Cirauqui-Cirauqui B, Bugés-Sánchez C, et al. Primary Hormone Therapy in Elderly Women with Hormone-Sensitive Locoregional Breast Cancer: Endocrine Therapy Alone Is a Reasonable Alternative in Selected Patients. Breast Care (Basel). 2015;10(3):179-83doi: 10.1159/000382112.
Quiroga-García, V., Cirauqui-Cirauqui, B., Bugés-Sánchez, C., Luna-Tomás, M. �. �., Castellà-Fernández, E. M., Mariscal-Martínez, A., & Margelí-Vila, M. (2015). Primary Hormone Therapy in Elderly Women with Hormone-Sensitive Locoregional Breast Cancer: Endocrine Therapy Alone Is a Reasonable Alternative in Selected Patients. Breast care (Basel, Switzerland), 10(3), 179-83. https://doi.org/10.1159/000382112
Quiroga-García, Vanesa, et al. "Primary Hormone Therapy in Elderly Women with Hormone-Sensitive Locoregional Breast Cancer: Endocrine Therapy Alone Is a Reasonable Alternative in Selected Patients." Breast care (Basel, Switzerland) vol. 10,3 (2015): 179-83. doi: https://doi.org/10.1159/000382112
Quiroga-García V, Cirauqui-Cirauqui B, Bugés-Sánchez C, Luna-Tomás MÁ, Castellà-Fernández EM, Mariscal-Martínez A, Margelí-Vila M. Primary Hormone Therapy in Elderly Women with Hormone-Sensitive Locoregional Breast Cancer: Endocrine Therapy Alone Is a Reasonable Alternative in Selected Patients. Breast Care (Basel). 2015 Jul;10(3):179-83. doi: 10.1159/000382112. Epub 2015 May 22. PMID: 26648829; PMCID: PMC4670958.
Copy Download .nbib Format: NLM
Economic Evaluetion of Fulvestrant 500 MG (F500) Versus Original Nonsteroidal Aromatase Inhibitors in Patient with Advanced Breast Canser in Russia (2 LINE THERAPY).

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research

Krysanov I, Tyapkina M.
PMID: 27202276
Value Health. 2014 Nov;17(7):A637. doi: 10.1016/j.jval.2014.08.2291. Epub 2014 Oct 26.

No abstract available.

Cite
Krysanov I, Tyapkina M. Economic Evaluetion of Fulvestrant 500 MG (F500) Versus Original Nonsteroidal Aromatase Inhibitors in Patient with Advanced Breast Canser in Russia (2 LINE THERAPY). Value Health. 2014;17(7):A637doi: 10.1016/j.jval.2014.08.2291.
Krysanov, I., & Tyapkina, M. (2014). Economic Evaluetion of Fulvestrant 500 MG (F500) Versus Original Nonsteroidal Aromatase Inhibitors in Patient with Advanced Breast Canser in Russia (2 LINE THERAPY). Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 17(7), A637. https://doi.org/10.1016/j.jval.2014.08.2291
Krysanov, I, and Tyapkina, M. "Economic Evaluetion of Fulvestrant 500 MG (F500) Versus Original Nonsteroidal Aromatase Inhibitors in Patient with Advanced Breast Canser in Russia (2 LINE THERAPY)." Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research vol. 17,7 (2014): A637. doi: https://doi.org/10.1016/j.jval.2014.08.2291
Krysanov I, Tyapkina M. Economic Evaluetion of Fulvestrant 500 MG (F500) Versus Original Nonsteroidal Aromatase Inhibitors in Patient with Advanced Breast Canser in Russia (2 LINE THERAPY). Value Health. 2014 Nov;17(7):A637. doi: 10.1016/j.jval.2014.08.2291. Epub 2014 Oct 26. PMID: 27202276.
Copy Download .nbib Format: NLM
Variations in the body mass index in Brazilian women undergoing adjuvant chemotherapy for breast cancer.

Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia

Ricci MD, Formigoni MC, Zuliani LM, Aoki DS, Mota BS, Filassi JR, Piato JR, Baracat EC.
PMID: 25493402
Rev Bras Ginecol Obstet. 2014 Nov;36(11):503-508. doi: 10.1590/s0100-720320140005081. Epub 2014 Nov 01.

PURPOSE: To evaluate variations in the body mass index in patients undergoing adjuvant chemotherapy for breast cancer, and to associate these changes with patient's age and adjuvant chemotherapy regimen.METHODS: We performed a retrospective cohort study in order to correlate...

Cite
Ricci MD, Formigoni MC, Zuliani LM, et al. Variations in the body mass index in Brazilian women undergoing adjuvant chemotherapy for breast cancer. Rev Bras Ginecol Obstet. 2014;36(11):503-508doi: 10.1590/s0100-720320140005081.
Ricci, M. D., Formigoni, M. C., Zuliani, L. M., Aoki, D. S., Mota, B. S., Filassi, J. R., Piato, J. R., & Baracat, E. C. (2014). Variations in the body mass index in Brazilian women undergoing adjuvant chemotherapy for breast cancer. Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia, 36(11), 503-508. https://doi.org/10.1590/s0100-720320140005081
Ricci, Marcos Desídérío, et al. "Variations in the body mass index in Brazilian women undergoing adjuvant chemotherapy for breast cancer." Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia vol. 36,11 (2014): 503-508. doi: https://doi.org/10.1590/s0100-720320140005081
Ricci MD, Formigoni MC, Zuliani LM, Aoki DS, Mota BS, Filassi JR, Piato JR, Baracat EC. Variations in the body mass index in Brazilian women undergoing adjuvant chemotherapy for breast cancer. Rev Bras Ginecol Obstet. 2014 Nov;36(11):503-508. doi: 10.1590/s0100-720320140005081. Epub 2014 Nov 01. PMID: 25493402.
Copy Download .nbib Format: NLM
Treatment of hormone positive uterine leiomyosarcoma with aromatase inhibitors.

Clinical sarcoma research

Thanopoulou E, Thway K, Khabra K, Judson I.
PMID: 25018868
Clin Sarcoma Res. 2014 Jun 26;4:5. doi: 10.1186/2045-3329-4-5. eCollection 2014.

BACKGROUND: Aromatase inhibitors (AIs) have not been used consistently as part of the management of hormone receptor positive uterine leiomyosarcomas (ULMS). As a result, the published data regarding the efficacy of AIs in this subtype of ULMS are sparse.METHODS:...

Cite
Thanopoulou E, Thway K, Khabra K, et al. Treatment of hormone positive uterine leiomyosarcoma with aromatase inhibitors. Clin Sarcoma Res. 2014;4:5doi: 10.1186/2045-3329-4-5.
Thanopoulou, E., Thway, K., Khabra, K., & Judson, I. (2014). Treatment of hormone positive uterine leiomyosarcoma with aromatase inhibitors. Clinical sarcoma research, 45. https://doi.org/10.1186/2045-3329-4-5
Thanopoulou, Eirini, et al. "Treatment of hormone positive uterine leiomyosarcoma with aromatase inhibitors." Clinical sarcoma research vol. 4 (2014): 5. doi: https://doi.org/10.1186/2045-3329-4-5
Thanopoulou E, Thway K, Khabra K, Judson I. Treatment of hormone positive uterine leiomyosarcoma with aromatase inhibitors. Clin Sarcoma Res. 2014 Jun 26;4:5. doi: 10.1186/2045-3329-4-5. eCollection 2014. PMID: 25018868; PMCID: PMC4094538.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 662 entries